Infectious Diseases

Antivirals, antibiotics, antifungals, and vaccines targeting bacterial, viral, and parasitic infections.

Companies

Pipeline Drugs

906

Key People

1047

Infectious Diseases Pipeline (906 drugs)

Commercial: 230Approved: 173Approved/Commercial: 63Phase 3: 61Preclinical: 47Pre-clinical: 46Phase 1: 39Phase 2: 30Phase 1/2: 17Clinical: 14Development: 13Not Specified: 13Research: 12Phase 2/3: 11Discovery: 9Research-Use Only: 9Phase 1b: 8Phase 2b: 6Pre-clinical to Commercial: 5Research-Use-Only: 5Not specified: 4Various Phases: 3Phase 1b/2: 3Commercial (RUO): 3Research/Discovery: 3Poised for Clinical: 3All Phases: 3Not Applicable: 3Phase (Early Clinical): 2Commercial/Approved: 2Phase 1b/2a: 2Launched: 2Lead Optimization: 2Clinical Development: 2IND Planned: 2Research/Development: 2Approved (EUA): 2Preclinical/Phase 1: 2Pre-clinical/Development: 2Various: 1Multiple Phases: 1Launch: 1Operational: 1Pre-Clinical/Phase 1: 1Phase 2a: 1R&D: 1Approved & Development: 1Research/Commercial: 1Development & Commercial: 1Emergency Use Authorization (Past): 1Filed/Development: 1Filed/Approved: 1IND Cleared: 1Phase (Partnered): 1Pre-clinical / Research: 1Phase 2/Phase 3: 1FDA Submission: 1Commercial/IVD Development: 1Commercial (IVD): 1Phase 2 (IND Active): 1Phase 2 Ready: 1Late-stage clinical: 1Approved/FDA-cleared: 1BLA Submitted: 1Phase 2b/3: 1Pre-Market Authorization: 1NDA/BLA Filed: 1Pre-clinical to Phase 3: 1Preclinical/Research: 1Prescription Product: 1Phase 2/3; Phase 2: 1Planned Phase 3: 1Not Disclosed: 1Discovery/Preclinical: 1Diagnostic Development: 1Pre-commercial: 1Service: 1N/A: 1Pre-IND: 1Platform Development: 1Concept: 1Approved (NPIP): 1Research Use Only: 1Platform Technology: 1Research & Regulated Studies: 1Phase 1a/1b: 1Research Use / Assay Development: 1

Drug	Company	Indication	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Rheumatoid Arthritis	Development	Active
Biological Age Predictor	Age Labs	Aging Assessment	Development	Active
COVID-19 Severity Prediction Test	Age Labs	COVID-19	Development	Active
BNT327	BioNTech	Multiple Cancer Types	Phase 2/3	Active
COVID-19 Vaccine (BNT162b2)	BioNTech	COVID-19 Prevention	Approved	Commercial
Individualized mRNA Cancer Immunotherapies	BioNTech	Various Solid Tumors	Phase 2/3	Active
Shared Antigen mRNA Cancer Vaccines	BioNTech	Cancer	Phase 2	Active
Next-generation mRNA Vaccines	BioNTech	Infectious Diseases	Phase 1	Active
Targeted Oncology Therapies	BioNTech	Cancer	Phase 1/2	Active
Keytruda (pembrolizumab)	Merck	Multiple Cancer Types	Commercial	Active
Gardasil/Gardasil 9	Merck	HPV Prevention	Commercial	Active
Lynparza (olaparib)	Merck	Various Cancers	Commercial	Active
Lenvima (lenvatinib)	Merck	Thyroid/Liver/Kidney Cancer	Commercial	Active
CORTONE (cortisone)	Merck	Rheumatoid Arthritis	Commercial	Active
Streptomycin	Merck	Tuberculosis	Commercial	Historical
Sulfaquinoxaline (S.Q.)	Merck	Animal Health - Coccidiosis	Commercial	Active
Stelara (ustekinumab)	Johnson & Johnson	Psoriasis, Crohn's Disease, Ulcerative Colitis	Approved	Commercial
Darzalex (daratumumab)	Johnson & Johnson	Multiple Myeloma	Approved	Commercial
Imbruvica (ibrutinib)	Johnson & Johnson	Blood Cancers	Approved	Commercial
Tremfya (guselkumab)	Johnson & Johnson	Psoriasis, Psoriatic Arthritis	Approved	Commercial
Erleada (apalutamide)	Johnson & Johnson	Prostate Cancer	Approved	Commercial
JNJ-4528 (CAR-T)	Johnson & Johnson	Multiple Myeloma	Phase 3	Active
JNJ-6372	Johnson & Johnson	Lung Cancer	Phase 2	Active
Nipocalimab	Johnson & Johnson	Myasthenia Gravis	Phase 3	Active
JNJ-1802	Johnson & Johnson	Treatment-Resistant Depression	Phase 2	Active
Yescarta (axicabtagene ciloleucel)	Gilead Sciences	Relapsed/Refractory Large B-Cell Lymphoma	Approved	Commercial
Tecartus (brexucabtagene autoleucel)	Gilead Sciences	Relapsed/Refractory Mantle Cell Lymphoma	Approved	Commercial
Bictegravir/TAF/FTC (Biktarvy)	Gilead Sciences	HIV-1 Infection	Approved	Commercial
Sofosbuvir/Velpatasvir (Epclusa)	Gilead Sciences	Chronic Hepatitis C	Approved	Commercial
Remdesivir (Veklury)	Gilead Sciences	COVID-19	Approved	Commercial
Lenacapavir	Gilead Sciences	HIV Prevention	Phase 3	Active
Magrolimab	Gilead Sciences	Myelodysplastic Syndrome	Phase 3	Active
Filgotinib	Gilead Sciences	Ulcerative Colitis	Phase 3	Active
Selonsertib	Gilead Sciences	NASH	Phase 3	Active
GS-5245	Gilead Sciences	Hepatitis B	Phase 2	Active
Blenrep (belantamab mafodotin)	GSK plc	Multiple Myeloma	Approved	Active
Jemperli (dostarlimab)	GSK plc	Endometrial Cancer	Approved	Active
Nucala (mepolizumab)	GSK plc	Severe Asthma	Approved	Active
Trelegy Ellipta	GSK plc	COPD, Asthma	Approved	Commercial
Shingrix	GSK plc	Herpes Zoster	Approved	Commercial
Arexvy	GSK plc	RSV	Approved	Commercial
GSK3844766	GSK plc	HIV	Phase 1	Active
GSK3640254	GSK plc	Pulmonary Arterial Hypertension	Phase 2	Active
Cabotegravir LA	GSK plc	HIV PrEP	Approved	Commercial
GSK4362676	GSK plc	Solid Tumors	Phase 1	Active
EYLEA (aflibercept)	Regeneron Pharmaceuticals	Wet AMD, diabetic macular edema, retinal vein occlusion	Approved	Commercial
Dupixent (dupilumab)	Regeneron Pharmaceuticals	Atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis	Approved	Commercial
Libtayo (cemiplimab)	Regeneron Pharmaceuticals	Cutaneous squamous cell carcinoma, basal cell carcinoma, NSCLC	Approved	Commercial
Praluent (alirocumab)	Regeneron Pharmaceuticals	High cholesterol	Approved	Commercial
Kevzara (sarilumab)	Regeneron Pharmaceuticals	Rheumatoid arthritis	Approved	Commercial